Skip to content

Respiratory Rate After Cesarean Delivery

Prospective Observational Study of Postoperative Respiratory Rate After Cesarean Delivery Among a Convenience Sample of Women Undergoing Spinal Anesthesia With and Without Neuraxial Opioids

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04250233
Enrollment
80
Registered
2020-01-31
Start date
2021-08-11
Completion date
2023-03-26
Last updated
2023-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cesarean Delivery; Neuraxial Opioids

Brief summary

The study proposal summarizes aspects related to respiratory rate in women who undergo spinal anesthesia for cesarean delivery who receive or do not receive neuraxial opioids

Detailed description

Respiratory monitoring device will be used to count respiratory rate continuously, as opposed to the intermittent nursing respiratory rate (RR) counts once per hour. The device counts respiration (RR) using a sticker placed by on the neck to detect vibrations made by respiration. This overcomes the specific limitation of capnography that requires wearing the nasal cannula. Prospective, observational study with institutional review board (IRB) approval. Women who undergo elective cesarean delivery under neuraxial block receive neuraxial opioids for postoperative analgesia. Potential study recruits will be approached prior to the cesarean delivery anesthesia assessment. Suitable women will be informed that neuraxial morphine is the gold-standard analgesia, however many women suffer nausea, vomiting and pruritus (itching) and may prefer an alternative analgesic or a lower dose of morphine. All women will receive intrathecal fentanyl as an adjuvant to the bupivacaine anesthesia. This fentanyl may also cause pruritus however this is limited to the 2-hour duration of the effect of the fentanyl. Women will be offered standard neuraxial anesthesia for cesarean delivery (heavy bupivacaine 10 mg; fentanyl 10-25mic; and low dose intrathecal morphine mic). Alternatively, women will be offered an alternative anesthesia option: 1) heavy bupivacaine 10 mg; fentanyl 10-15 mic with an ultra-low dose, 50 mic of morphine, or 2) heavy bupivacaine 10 mg; fentanyl 10-25 mic without intrathecal morphine + postoperative bilateral quadratus lumborum block (QLB), transversus abdominis plane (TAP) or erector spinus block (ESP). For patients who select block without intrathecal morphine, the choice of block will depend on anesthesiologist's decision.

Interventions

DEVICERespiratory Monitor

All women receive a respiratory rate monitor after cesarean delivery. We anticipate that at least 30 women will receive standard dose neuraxial block, and aim to have a cohort of 20-30 women who receive non-standard dose (Group 20 in order to compare respiratory rates.

Sponsors

Stanford University
CollaboratorOTHER
Tel-Aviv Sourasky Medical Center
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

* American Society of Anesthesiologists physical status class II or III * age between 18 and 50 * gestational age greater than 37 completed weeks * singleton pregnancy. In contrast to previous studies * we do not plan to exclude obese women and those with suspected sleep apnea.

Exclusion criteria

* Contraindication for epidural analgesia (bleeding diathesis, neuropathy, severe scoliosis, previous spine surgery, local anesthetic allergy) * narcotic administration in the previous 2 hours * inability to adequately understand the consent form * moderate-severe asthma, inability to receive morphine * sensitivity to sticker * skin conditions.

Design outcomes

Primary

MeasureTime frameDescription
Respiratory rate ≤8up to 24 hoursOur primary study aim is to report the number of women with RR≤8 at any time point after the cesarean delivery using the continuous respiratory monitoring device.

Secondary

MeasureTime frameDescription
oxygen saturationup to 24 hours\- To report the minimum/maximum values for: oxygen saturation for women who undergo cesarean delivery and receive standard low-dose neuraxial opioids and to compare to other groups.
heart rateup to 24 hours\- To report the minimum/maximum values for: heart rate for women who undergo cesarean delivery and receive standard low-dose neuraxial opioids and to compare to other groups.
apneaup to 24 hours\- To report the frequency of apnea for women who undergo cesarean delivery and receive standard low-dose neuraxial opioids and to compare to other groups.
side effectsup to 24 hoursincidence ie no of women with and without pruritus, nausea, vomiting, other side effects of analgesia and compare between groups
additional analgesiaup to 24 hourspost operative analgesia used for each patient in 24 hours (paracetamol, ibuprofen, optalgin, other) and compare between groups
respiratory rate per minup to 24 hoursTo report the minimum/maximum values for: respiratory rate per min among women who receive standard low dose neuraxial opioids for postoperative analgesia and to compare to other groups
duration of monitor periodup to 24 hoursduration of use of monitor (pulse oximeter, RR, HR) - all and each of the components
nurse outcomesup to 24 hoursnurse measured outcomes - the number of the RR recorded, and compare between groups - women with and without resp depression
patient experienceup to 24 hourspatient will be asked for verbal descriptions after being prompted - how did you find the experience of using the device to assess patient experience of the device (discomfort, nursing interference, mobility interference, family visit interference, itchy, nausea, others)
patient anesthesia selectionup to 24 hoursTo report the number of women who select each of the anesthesia modalities offered (standard low dose; ultra-low dose morphine; or truncal nerve block (QLB/TAP/ESP).
antiemeticup to 24 hoursantiemetic administration for each patient in 24 hours and compare between groups - women with and without resp depression

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026